Psychedelic-assisted therapies have resulted in transformative experiences for many individuals, as well as the practitioners who have worked with them. However, despite the wealth of anecdotal evidence gathered to date, the scientific basis for the use of psychedelics remains somewhat limited. In addition to the need for more basic science about how psychedelics work on the brain, psychedelic-assisted therapies will benefit from the development of best practice standards, modernized regulatory policy, practitioner training, and public education.
Queen’s Health Sciences plans to be a leader in this field. As such, the Faculty has created a research collaborative that will serve as an interdisciplinary space for research, innovation and knowledge translation in the field of psychedelics. The collaborative will serve as a space to connect expertise across campus and stakeholders and partners in the broader community.
The Dimensions Health Research Collaborative will take a multi-pronged approach to supporting research and innovation in psychedelic-focused therapies. In addition to bringing together collaborators from across the university, the collaborative will allow the faculty to build relationships with stakeholders and experts in the community.
Anticipated benefits include:
- Furthering existing research and broadening the scope of psychedelic-assisted therapies and the psychedelics sector
- Building awareness of the healing potential of psychedelics, and supporting early entry into the scientific and regulatory landscape;
- Laying a foundation for the development of policy that is ethical and evidence-informed;
- Supporting training, education, and knowledge translation for healthcare providers;
- Aiding the development of best practice standards to ensure the safety, quality, and effectiveness of therapies, helping to ensure the sector’s long-term growth and sustainability
The collaborative will be aligned with Faculty of Health Sciences' commitment to supporting Black, Indigenous and People of Colour (BIPOC) learners, staff and faculty, and the Equity, Diversity and Inclusion (EDI) initiative, launched in fall 2020.
The Dimensions Health Research Collaborative was founded with support from the Dimensions Health Fund in support of the Study of Psychedelics, established by Dimensions Health Centres (“Dimensions”). For further information on the collaborative, including opportunities to partner, please contact David Clements, executive director, at email@example.com.
Queen's co-releases rapid review of the evidence on psychedelics as medicine
Oct 13, 2022
Psychedelic research is rapidly expanding, and the potential therapeutic benefits of various psychedelic compounds have caught the attention of clinicians, scientists, policy makers and the general public. This one-of-a-kind publication, produced in collaboration with the Homewood Research Institute, is a rapid review of published literature on psychedelics as medicines and serves to bring together and explore a vast body of varied literature. As an ambtious act of knowledge synthesis and translation, it aims to inform the next generation of research and influence emerging practices of clinical care.
Queen’s appoints Psychedelic Science Advisory Committee
May 9, 2022
Queen’s Health Sciences is pleased to announce the appointment of six members to the university’s first Psychedelic Science Advisory Committee.
The committee provides advice on science matters related to the field of psychedelics and human health to the Dimensions Health Research Collaborative, including timely scientific, technical, and methodological advice related to the conduct of research in psychedelics. This includes vetting and advice related to the pursuit of pre-clinical and clinical research opportunities, as well as support for translational research, implementation science, and health services and policy research.
“There is currently significant optimism about how psychedelics may improve human health, including through psychedelic-assisted therapy,” says Jane Philpott, Dean, Queen’s Health Sciences. “The committee will help guide Queen’s as we conduct research and knowledge translation to provide policy leaders, clinicians and patients with strong evidence to support their decisions.”
“The field of psychedelics research is expanding rapidly, in Canada and around the world,” says David Clements, executive director of the Dimensions Health Research Collaborative. “I am grateful to these individuals for coming forward and volunteering their time and expertise to guide us in this emerging area.”
Members of the committee are:
- Claudio Soares (chair) is a medical doctor and psychiatrist, Head of the Department of Psychiatry at Queen’s, and Executive Lead for the Canadian Biomarker Integration Network in Depression (CAN-BIND). He is also a clinical researcher with large experience in clinical trials. His clinical and research work has been focused on the management of mood and anxiety disorders across the life span, including: (1) Women’s mental health and the role of hormones as precipitating factors or treatment options for depression. (2) Signature markers of treatment response to new interventions in Psychiatry (e.g., antidepressants, ketamine, rTMS, and emerging treatments such as psychedelics) mobile health technologies and wearables for real-time symptom monitoring and relapse prevention, and (3) The management of depression, anxiety, pain and other psychological symptoms in Oncology and Palliative Medicine settings.
- Jean Mathews is a palliative care physician and assistant professor in the School of Medicine at Queen’s. His areas of interest are global oncology palliative care, advanced pain management, and telehealth palliative care. He has been published in several peer-reviewed oncology and palliative care journals and he is working on research projects in Canada and in India, to improve access to early palliative care. He completed a clinical and research fellowship in palliative care at University of Toronto, and prior to that, was working in palliative care in India. His interest in psychedelic research is specifically focused on their applications for existential distress and other physical and psychosocial suffering in patients with life-limiting illnesses. While in Toronto, he assisted with recruitment for a study investigating the role of intranasal ketamine for existential distress for patients admitted to the palliative care unit and requesting Medical Assistance in Dying.
- Keith Williams is Director of Research and Social Innovation for the First Nations Technical Institute, Tyendinaga Mohawk Territory. He currently sits on the Oregon Psilocybin Advisory Board – Products Subcommittee. Keith has a master’s degree in mycology and a Ph.D. in higher education looking at the potential for food systems transformation in an Indigenous-run and community-based Indigenous institute. Keith believes that psychedelics hold significant promise for reconnecting humanity with our more-than-human kin (all our relations). He is also interested in ensuring that the psychedelic renaissance does not exclude Indigenous Peoples and wants to build bridges with Indigenous communities for research and treatment.
- Don Husereau is an Adjunct Professor of Medicine at The University of Ottawa. He does freelance health care research and works with private and public sector life sciences organizations to help them understand the value of health technology and its implications for health and innovation policy.
- Bob Nakagawa B.Sc.(Pharm.), FCSHP, ACPR, has had an extensive career in government, professional regulation, health administration and pharmacy. Most recently, he served as Registrar/ CEO of the College of Pharmacists of BC. Prior to that he was Assistant Deputy Minister for Pharmaceutical Services in the BC Ministry of Health. He has served in numerous leadership positions, including President of the College of Pharmacists of BC, President of the Canadian Society of Hospital Pharmacists, Chair of the Medical Services Commission of BC, the Federal Pharmacy and Therapeutics Committee and BC’s Drug Benefits Council. He is currently a member of the Oversight Committee for the Therapeutics Initiative at UBC.
- Elena Koning is a PhD Student in Clinical Neuroscience at Queen’s University. She has investigated the use of psilocybin as a novel treatment for dysfunctional eating behavior in psychiatric illness and has investigated the concept of “metabolic jet lag” in bipolar disorder; designed and planned a feasibility study focused on the investigation of eating rhythm disruption and clinical outcomes in bipolar disorder and identified and characterized eating behavioral phenotypes in the mood disorder population as well as implications for clinical care.
Committee members began their terms on April 1, 2022 and will serve for an initial term of two years. Meanwhile, Queen’s continues to recruit for up to four additional members for the committee, to bring additional expertise and viewpoints. Priority will be given to appointing women, to ensure a balance of sex and gender on the committee. The next round of recruitment will continue aligned with Faculty of Health Sciences' commitment to supporting Black, Indigenous and People of Colour (BIPOC) learners, staff and faculty, and the Equity, Diversity and Inclusion (EDI) initiative, launched in fall 2020.
The Dimensions Health Research Collaborative was launched in summer 2021 and is enabled by a generous donation from Dimensions Health Centres.
Call for Future Members: Psychedelic Science Advisory Committee
9 May 2022
The Dimensions Health Research collaborative continues to seek volunteer members for its inaugural Psychedelic Science Advisory Committee, which will provide advice to the Collaborative on science matters related to the field of psychedelics and human health. This includes the pursuit of pre-clinical and clinical research, as well as translational research, implementation science, and health services and policy research.
Members are chosen based on a broad array of factors including academic background, membership in scientific and health professional societies, and track record in fields related to the area of psychedelic research, and/or treatment. In addition, membership of the Committee will reflect the value of various areas of expertise, knowledge, and perspectives, including health professionals, scientists, entrepreneurs, patients, and community members. The next round of appointments is planned for Fall 2022.
The committee’s collective expertise will include, but not be limited to:
- Clinical trial design
- Medicinal chemistry
- Health services and policy research
- Regulatory science
- Palliative medicine
- Public health
The committee currently has six members, and will not exceed ten. Members are appointed for an initial two-year term, which may be extended for an additional two years. Membership may be periodically adjusted to ensure the appropriate representation of expertise and experience.
Please note that, in alignmnent with Faculty commitments in the area of equity, diversity and inclusion and the current membership of the committee, priority will be given to applicants from equity-seeking groups, including women and those who identify as women.
Potential members should provide a brief CV and cover letter to the Executive Director, Psychedelics Research. Terms of Reference for the committee can be found here
Ron Shore appointed as research scientist with the Dimensions Health Research Collaborative
December 15, 2021
Queen’s Health Sciences is pleased to announce the appointment of Ron Shore as research scientist with the Dimensions Health Research Collaborative, effective December 6, 2021.
Ron Shore (he/him) is a doctoral candidate in the School of Kinesiology and Health Studies, where he has taught as an adjunct, continuing adjunct and teaching fellow for 15 years. Ron is also a part-time Professor at the University of Ottawa, where he teaches Psychedelics, Politics and Harm reduction to both graduate and undergraduate students.
Ron's PhD research is on the clinical application of psilocybin. He has several forthcoming papers from his doctoral research including: Mapping Psilocybin Therapy, a Scoping Review, Behavioural Investigations of Psilocybin in Animals: A Scoping Review, and Psychedelics, Safety and Clinical Trial Design.
Ron has a B.A. in philosophy and Masters in Public Administration (concentration in health policy) both from Queen's, and is the founder of Kingston's Street Health Centre. Ron spent 23 years in front-line harm reduction, community and public health prior to returning to school for his PhD, which he defends in early 2022.
David Clements appointed Executive Director, Psychedelics Research
June 1, 2021
Dr. Jane Philpott, Dean, Faculty of Health Sciences at Queen’s University, has appointed David Clements as Executive Director, Dimensions Health Research Collaborative, effective June 1, 2021. In this part-time role, he will work closely with scientists and stakeholders at Queen’s, in the Kingston community, and beyond. Mr. Clements will serve concurrently as senior advisor, innovation strategy and policy, for Queen's Health Sciences.
The Collaborative is enabled by the Dimensions Health Fund in support of the Study of Psychedelics, established by Dimensions Health Centres (“Dimensions”). The collaborative will serve as a space to connect expertise across campus and stakeholders and partners in the broader community.
Mr. Clements has more than two decades experience working in health policy, planning, strategy, communications and stakeholder engagement. He has held senior management roles in organizations including Health Canada, the Canadian Institutes of Health Research, the Canadian Institute for Health Information and the Canadian Health Services Research Foundation. In 2014 and 2015, he served as executive director of the federal advisory panel on healthcare innovation, and he has also served as a senior advisor and communications director for Canada’s minister of health.
Mr. Clements holds a BA at the University of Victoria, as well as an MPA from the School of Policy Studies at Queen’s, with a concentration in health policy. He also pursued doctoral studies at the Vrije Universiteit Amsterdam.